Patents by Inventor Nobuyoshi Umeda
Nobuyoshi Umeda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220340869Abstract: Highly proliferative mesenchymal stem cells (MSCs) may be useful for the large-scale and rapid production of a cell preparation, and a cell population may include the mesenchymal stem cells. A cell population may include mesenchymal stem cells derived from a fetal appendage, wherein, in the cell population, the proportion of CD105+ mesenchymal stem cells is 50% or more, the proportion of CD200+ mesenchymal stem cells is less than 10%, and the proportion of CD106+ mesenchymal stem cells is less than 5%.Type: ApplicationFiled: June 27, 2022Publication date: October 27, 2022Applicant: KANEKA CORPORATIONInventors: Masahiro Hayashi, Yuta Kita, Nobuyoshi Umeda
-
Patent number: 11401502Abstract: An object of the present invention is to provide highly proliferative mesenchymal stem cells (MSCs) useful for the large-scale and rapid production of a cell preparation, and a cell population comprising the mesenchymal stem cells. According to the present invention, there is provided a cell population comprising mesenchymal stem cells derived from the fetal appendage, wherein, in the cell population, the proportion of CD105+ mesenchymal stem cells is 50% or more, the proportion of CD200+ mesenchymal stem cells is less than 10%, and the proportion of CD106+ mesenchymal stem cells is less than 5%.Type: GrantFiled: November 14, 2017Date of Patent: August 2, 2022Assignee: KANEKA CORPORATIONInventors: Masahiro Hayashi, Yuta Kita, Nobuyoshi Umeda
-
Publication number: 20220233600Abstract: This invention provides a cell population comprising mesenchymal cells capable of forming a cell sheet that can be spontaneously detached from a substrate. In such cell population comprising mesenchymal cells, the proportion of cells positive for CD324 is 70% or more and the proportion of mesenchymal cells positive for CD90 is 90% or more.Type: ApplicationFiled: June 12, 2020Publication date: July 28, 2022Applicant: KANEKA CORPORATIONInventors: Nobuyoshi UMEDA, Kohei OGURA
-
Publication number: 20210085828Abstract: The present invention provides a multilayer matrix comprising at least two layers in which the first layer comprises a bioresorbable material and the second layer comprises a bioadhesive material, wherein the second layer contains cells. A method for producing a multilayer matrix and the use of a multilayer matrix are also provided.Type: ApplicationFiled: March 22, 2019Publication date: March 25, 2021Applicants: QUEEN MARY UNIVERSITY OF LONDON, KANEKA CORPORATIONInventors: Ken SUZUKI, Nobuyoshi UMEDA
-
Publication number: 20200368291Abstract: An object of the present invention is to provide a cell population comprising safe adherent stem cells maintaining a normal karyotype and a method for producing the cell population, and a pharmaceutical composition comprising the cell population. According to the present invention, a production method of a cell population comprising adherent stem cells, comprising obtaining a cell population in which the proportion of KCNAB1-positive adherent stem cells in the cell population is 85% or more, is provided.Type: ApplicationFiled: December 28, 2018Publication date: November 26, 2020Applicant: KANEKA CORPORATIONInventors: Nobuyoshi UMEDA, Keita INO, Chiho KOBAYASHI
-
Publication number: 20200360444Abstract: An object of the present invention is to provide a cell population comprising adherent stem cells and exhibiting high immunosuppressive activity and/or proliferative property and a production method of the cell population, and a pharmaceutical composition comprising the cell population. The present invention provides a production method of a cell population comprising adherent stem cells, the method comprising obtaining a cell population having the following cell characteristics (a) and (b): (a) the cell population is positive for expressions of PLIN2 gene and NEFM gene, (b) the cell population satisfies the relative expression level of PLIN2 gene to the expression level of SDHA gene of 1.50 or more.Type: ApplicationFiled: December 28, 2018Publication date: November 19, 2020Applicant: KANEKA CORPORATIONInventors: Keita INO, Chiho KOBAYASHI, Sho YAMAGUCHI, Nobuyoshi UMEDA
-
Patent number: 10653825Abstract: Provided is a priming method including a step of filling a priming liquid in a hollow-fiber membrane module in which hollow-fiber membranes are packed in a vessel having an inlet port, an outlet port, and a filtrate discharge port at a linear velocity of 20 cm/min or more and 550 cm/min or less through the inlet port or the outlet port in an amount of 15% or more relative to a volume of the hollow-fiber membrane module. According to the present invention, the effective filtration area at the time of cell suspension treatment is increased, and the recovery rate of cells and the filtration rate can be improved. Further, since the cell treatment can be completed while maintaining the closed environment, the obtained cells can be provided for therapeutic applications.Type: GrantFiled: April 28, 2017Date of Patent: May 19, 2020Assignee: KANEKA CORPORATIONInventors: Nobuyoshi Umeda, Shuhei Taniguchi
-
Patent number: 10533151Abstract: In a method for producing a cell concentrate using a cell suspension treatment system including a storage container of a cell suspension, which has a solution inlet port, a circulation outlet port, and a circulation inlet port, a cell suspension treatment device for concentrating the cell suspension by separating liquid from the cell suspension by filtration, the device including a container having a cell suspension introduction port, a cell suspension lead-out port, and a filtrate outlet, which is filled with a hollow fiber separation membrane, a circulation circuit for concentrating the cell suspension while circulating the cell suspension between the storage container and the cell suspension treatment device, a collection container of a cell concentrate obtained by concentration, a collection path for feeding the cell concentrate to the collection container, an injection path for injecting a solution into the solution inlet port of the storage container, and a detecting unit.Type: GrantFiled: September 26, 2018Date of Patent: January 14, 2020Assignee: KANEKA CORPORATIONInventors: Shuhei Taniguchi, Nobuyoshi Umeda, Takaaki Sakashita, Hiroshi Sakurai
-
Publication number: 20190270964Abstract: Highly proliferative mesenchymal stem cells (MSCs) may be useful for the large-scale and rapid production of a cell preparation, and a cell population may include the mesenchymal stem cells. A cell population may include mesenchymal stem cells derived from a fetal appendage, wherein, in the cell population, the proportion of CD105+ mesenchymal stem cells is 50% or more, the proportion of CD200+ mesenchymal stem cells is less than 10%, and the proportion of CD106+ mesenchymal stem cells is less than 5%.Type: ApplicationFiled: November 14, 2017Publication date: September 5, 2019Applicant: KANEKA CORPORATIONInventors: Masahiro Hayashi, Yuta Kita, Nobuyoshi Umeda
-
Publication number: 20190024037Abstract: In a method for producing a cell concentrate using a cell suspension treatment system including a storage container of a cell suspension, which has a solution inlet port, a circulation outlet port, and a circulation inlet port, a cell suspension treatment device for concentrating the cell suspension by separating liquid from the cell suspension by filtration, the device including a container having a cell suspension introduction port, a cell suspension lead-out port, and a filtrate outlet, which is filled with a hollow fiber separation membrane, a circulation circuit for concentrating the cell suspension while circulating the cell suspension between the storage container and the cell suspension treatment device, a collection container of a cell concentrate obtained by concentration, a collection path for feeding the cell concentrate to the collection container, an injection path for injecting a solution into the solution inlet port of the storage container, and a detecting unit.Type: ApplicationFiled: September 26, 2018Publication date: January 24, 2019Applicant: KANEKA CORPORATIONInventors: Shuhei TANIGUCHI, Nobuyoshi UMEDA, Takaaki SAKASHITA, Hiroshi SAKURAI
-
Patent number: 10113144Abstract: In a method for producing a cell concentrate using a cell suspension treatment system including a storage container of a cell suspension, which has a solution inlet port, a circulation outlet port, and a circulation inlet port, a cell suspension treatment device for concentrating the cell suspension by separating liquid from the cell suspension by filtration, the device including a container having a cell suspension introduction port, a cell suspension lead-out port, and a filtrate outlet, which is filled with a hollow fiber separation membrane, a circulation circuit for concentrating the cell suspension while circulating the cell suspension between the storage container and the cell suspension treatment device, a collection container of a cell concentrate obtained by concentration, a collection path for feeding the cell concentrate to the collection container, an injection path for injecting a solution into the solution inlet port of the storage container, and a detecting unit.Type: GrantFiled: July 16, 2014Date of Patent: October 30, 2018Assignee: KANEKA CORPORATIONInventors: Shuhei Taniguchi, Nobuyoshi Umeda, Takaaki Sakashita, Hiroshi Sakurai
-
Patent number: 9746453Abstract: The present invention has an object to solve the problem in a method for separating nucleated cells from a cell-containing fluid using a cell separation filter. Specifically, the present invention provides a cell separation filter and a method for preparing cells using a cell separation filter, which are capable of reducing unnecessary cell contamination in a nucleated cell fraction without needs of designing non-woven fabrics to suit cell species to be recovered. The present invention also provides a cell separation filter and a method for preparing cells using the filter capable of improving the recovery yield of nucleated cells. The present invention provides a cell separation filter comprising: a container having an inlet and an outlet, an adsorbent filled in the container, and a partition having an opening, the partition separating the adsorbent.Type: GrantFiled: October 24, 2014Date of Patent: August 29, 2017Assignee: KANEKA CORPORATIONInventor: Nobuyoshi Umeda
-
Publication number: 20170232180Abstract: Provided is a priming method including a step of filling a priming liquid in a hollow-fiber membrane module in which hollow-fiber membranes are packed in a vessel having an inlet port, an outlet port, and a filtrate discharge port at a linear velocity of 20 cm/min or more and 550 cm/min or less through the inlet port or the outlet port in an amount of 15% or more relative to a volume of the hollow-fiber membrane module. According to the present invention, the effective filtration area at the time of cell suspension treatment is increased, and the recovery rate of cells and the filtration rate can be improved. Further, since the cell treatment can be completed while maintaining the closed environment, the obtained cells can be provided for therapeutic applications.Type: ApplicationFiled: April 28, 2017Publication date: August 17, 2017Applicant: KANEKA CORPORATIONInventors: Nobuyoshi UMEDA, Shuhei TANIGUCHI
-
Publication number: 20160168529Abstract: In a method for producing a cell concentrate using a cell suspension treatment system including a storage container of a cell suspension, which has a solution inlet port, a circulation outlet port, and a circulation inlet port, a cell suspension treatment device for concentrating the cell suspension by separating liquid from the cell suspension by filtration, the device including a container having a cell suspension introduction port, a cell suspension lead-out port, and a filtrate outlet, which is filled with a hollow fiber separation membrane, a circulation circuit for concentrating the cell suspension while circulating the cell suspension between the storage container and the cell suspension treatment device, a collection container of a cell concentrate obtained by concentration, a collection path for feeding the cell concentrate to the collection container, an injection path for injecting a solution into the solution inlet port of the storage container, and a detecting unit.Type: ApplicationFiled: July 16, 2014Publication date: June 16, 2016Applicant: KANEKA CORPORATIONInventors: Shuhei TANIGUCHI, Nobuyoshi UMEDA, Takaaki SAKASHITA, Hiroshi SAKURAI
-
Publication number: 20150044767Abstract: The present invention has an object to solve the problem in a method for separating nucleated cells from a cell-containing fluid using a cell separation filter. Specifically, the present invention provides a cell separation filter and a method for preparing cells using a cell separation filter, which are capable of reducing unnecessary cell contamination in a nucleated cell fraction without needs of designing non-woven fabrics to suit cell species to be recovered. The present invention also provides a cell separation filter and a method for preparing cells using the filter capable of improving the recovery yield of nucleated cells. The present invention provides a cell separation filter comprising: a container having an inlet and an outlet, an adsorbent filled in the container, and a partition having an opening, the partition separating the adsorbent.Type: ApplicationFiled: October 24, 2014Publication date: February 12, 2015Applicant: KANEKA CORPORATIONInventor: Nobuyoshi UMEDA
-
Publication number: 20140072954Abstract: The present invention aims to provide a mononuclear cell preparation material capable of improving the mononuclear cell recovery while reducing granulocyte contamination, and a mononuclear cell preparation method which improves the mononuclear cell recovery. Provided is a mononuclear cell preparation material for removing granulocytes from blood to prepare mononuclear cells, which includes a nonwoven fabric made of a polyamide resin. Also provided is a method for preparing mononuclear cells using a device with the mononuclear cell preparation material packed in a container, the method including the steps of: (A) passing blood through the mononuclear cell preparation device from an inlet side to an outlet side of the device, thereby capturing granulocytes in the device; and (B) passing a washing solution through the mononuclear cell preparation device from the inlet side to the outlet side of the device, thereby recovering mononuclear cells remaining in the device.Type: ApplicationFiled: April 2, 2012Publication date: March 13, 2014Applicant: KANEKA CORPORATIONInventors: Nobuyoshi Umeda, Nobuhiko Sato, Ayako Tsukamoto
-
Patent number: 5392632Abstract: A small volume prover is disclosed which is compact and capable of obtaining highly reliable measurement, keeping a highly accurate base volume without being affected by temperature and pressure of fluid to be measured.The prover includes a cylindrical outer housing having a fluid inlet and a fluid outlet spaced apart from each other, a cylindrical measuring conduit having both open ends and first and second sets of fluid ports radially made in a wall thereof and coaxially mounted within the outer housing and an annular wall mounted between the outer housing and the measuring conduit at the position between the measuring conduit open end and the first set of ports thereof to form an upstream annular passage and a downstream annular passage. During proving preparation a piston is restrained by a piston actuator provided in the outlet-side end of the outer housing to permit the fluid to pass through the annular passage.Type: GrantFiled: August 12, 1992Date of Patent: February 28, 1995Assignee: Oval Engineering Co.,Ltd.Inventors: Nobuyoshi Umeda, Toshio Seo, Yuzirou Nagamori, Kenichi Matsuoka, Shingo Gomi